G protein-coupled receptors

2020 Market Spotlight: Axial Spondyloarthritis (axSpA)

Retrieved on: 
Friday, April 3, 2020

DUBLIN, April 3, 2020 /PRNewswire/ -- The "Market Spotlight: Axial Spondyloarthritis (axSpA) 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 3, 2020 /PRNewswire/ -- The "Market Spotlight: Axial Spondyloarthritis (axSpA) 2020" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, and IL-17.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for axSpA, followed by AbbVie

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline

Retrieved on: 
Thursday, April 2, 2020

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).
  • Under terms of the agreement, Horizon acquired Curzion for a $45 million upfront cash payment with additional payments contingent on the achievement of development and regulatory milestones.
  • The U.S. prevalence of dcSSc is approximately 30,000 and the disease carries one of the highest mortality rates among rheumatic diseasesi.
  • Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases.

Global Polycystic Ovary Syndrome (PCOS) Market Study, 2015-2026: Key Marketed & Pipeline Drugs, Clinical Trials, Patent Information, 10-Year Disease Incidence Forecast, Licensing & Acquisition Deals - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020

This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.

Key Points: 
  • This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
  • The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor.
  • Therapies in the pipeline for PCOS focus on targets such as AMP-activated protein kinase, neurokinin receptor, and gonadotropin-releasing hormone receptor.
  • Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.

2020 Market Spotlight: Insomnia -- Eisai Buys Out Global Rights to Lemborexant - ResearchAndMarkets.com

Retrieved on: 
Monday, March 30, 2020

It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).

Key Points: 
  • It is estimated that Asia had the largest number of prevalent cases in 2017 (675.7 million cases).
  • The approved drugs in the insomnia space target GABA-A receptor, hypocretin/orexin receptor, chloride channel 2, chloride, melatonin receptor, histamine H1 receptor, and potassium channels.
  • The largest proportion of industry-sponsored drugs in active clinical development for insomnia are in Phase III, with only one drug in the NDA/BLA phase.
  • Takeda leads the industry sponsors with the highest overall number of clinical trials for insomnia, followed by Merck & Co.

2020 Insights into Calcitonin Gene Related Peptide Type 1 Receptor - Featuring Adepthera, Allergan and Amgen Among Others

Retrieved on: 
Wednesday, March 25, 2020

According to this report the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules.

Key Points: 
  • According to this report the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 6 molecules.
  • Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Calcitonin receptor-like (CALCRL) also known as the calcitonin receptor-like receptor (CRLR) is a G protein-coupled receptor.
  • The report 'Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
  • It also reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development with respective active and dormant or discontinued projects.

Glucagon Receptor Structures Reveal G protein Specificity Mechanism

Retrieved on: 
Thursday, March 19, 2020

This study offers valuable insights into pleiotropic GPCR-G protein coupling and G protein specificity.

Key Points: 
  • This study offers valuable insights into pleiotropic GPCR-G protein coupling and G protein specificity.
  • Although GCGR couples to both G proteins through the common pocket, it does so with different interaction patterns, which account for G protein specificity.
  • Based on the structures of GCGR-G protein complexes, the researchers performed extensive functional studies using techniques such as mutagenesis, G protein activation and cell signaling to investigate the roles of key residues in the receptor-G protein binding interface in Gs and Gi activation.
  • The results show that conformational differences of intracellular loops and residue side chains in the receptor are sufficient to guide G protein selectivity.

Glucagon Receptor Structures Reveal G protein Specificity Mechanism

Retrieved on: 
Thursday, March 19, 2020

This study offers valuable insights into pleiotropic GPCR-G protein coupling and G protein specificity.

Key Points: 
  • This study offers valuable insights into pleiotropic GPCR-G protein coupling and G protein specificity.
  • Although GCGR couples to both G proteins through the common pocket, it does so with different interaction patterns, which account for G protein specificity.
  • Based on the structures of GCGR-G protein complexes, the researchers performed extensive functional studies using techniques such as mutagenesis, G protein activation and cell signaling to investigate the roles of key residues in the receptor-G protein binding interface in Gs and Gi activation.
  • The results show that conformational differences of intracellular loops and residue side chains in the receptor are sufficient to guide G protein selectivity.

Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia

Retrieved on: 
Wednesday, February 12, 2020

Liminal BioSciences' research involves the study of several G-protein-coupled-receptors, known as free fatty acid receptors (FFAR's).

Key Points: 
  • Liminal BioSciences' research involves the study of several G-protein-coupled-receptors, known as free fatty acid receptors (FFAR's).
  • Liminal BioSciences has also leveraged its experience in bioseparation technologies through its wholly-owned subsidiary Prometic Bioproduction Inc. to isolate and purify biopharmaceuticals from human plasma.
  • Liminal BioSciences has active business operations in Canada, the United Kingdom and the United States.
  • This press release contains forward-looking statements about Liminal BioSciences' objectives, strategies and businesses and unaudited financial information that involve risks and uncertainties.

Tempest Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPST-1495 and Welcomes New Investors

Retrieved on: 
Thursday, January 30, 2020

Food and Drug Administration(FDA) has cleared the company's investigational new drug (IND) application for TPST-1495, a small molecule dual antagonist of the prostaglandin receptors EP2 and EP4.

Key Points: 
  • Food and Drug Administration(FDA) has cleared the company's investigational new drug (IND) application for TPST-1495, a small molecule dual antagonist of the prostaglandin receptors EP2 and EP4.
  • FDAclearance of the IND enables Tempest to initiate its planned Phase1a/1bclinical trial in patients withadvancedsolid tumors.
  • Tempest also announced that healthcare investors Lyfe Capital and Rock Springs Capital Management have made equity investments in the company.
  • Tempest is a clinical-stage biotechnology company advancing small molecules that combine both precision and immune-mediated mechanisms to modulate anti-tumor pathways.

Cerevel Therapeutics Initiates Phase 1 Clinical Trial of CVL-936, an Investigational Medicine in Development to Treat Substance Use Disorder

Retrieved on: 
Thursday, January 30, 2020

We look forward to the results of this trial which will generate key safety, tolerability and pharmacokinetic data to inform further clinical development of CVL-936 in patients.

Key Points: 
  • We look forward to the results of this trial which will generate key safety, tolerability and pharmacokinetic data to inform further clinical development of CVL-936 in patients.
  • The trial will be conducted at a single center and will include up to 27 subjects across three cohorts.
  • CVL-936 is a selective dopamine D3-preferring, D2/D3 receptor subtype antagonist in clinical development for the treatment of substance use disorder.
  • Cerevel Therapeutics has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including Parkinsons disease, epilepsy, schizophrenia and substance use disorder.